Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
grade D 15.89 -25.47% -5.43
OMER closed down 25.47 percent on Tuesday, August 11, 2020, on 7.94 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical OMER trend table...

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
Shooting Star Candlestick Bearish -25.47%
Crossed Above 200 DMA Bullish -25.47%
Crossed Above 50 DMA Bullish -25.47%
MACD Bullish Centerline Cross Bullish -25.47%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Medicine Health Biopharmaceutical Surgery Inflammation Disorders Clinical Trial Schizophrenia Ophthalmology Wet Age Related Macular Degeneration Clinical Research Movement Disorders Cataract Cognitive Disorders Surgical Specialties Urology Paroxysmal Nocturnal Hemoglobinuria Arthroscopy Hemolytic Uremic Syndrome

Is OMER a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.46
52 Week Low 8.5
Average Volume 879,215
200-Day Moving Average 14.18
50-Day Moving Average 14.63
20-Day Moving Average 14.39
10-Day Moving Average 14.52
Average True Range 1.72
ADX 19.47
+DI 50.06
-DI 23.13
Chandelier Exit (Long, 3 ATRs ) 20.31
Chandelier Exit (Short, 3 ATRs ) 17.69
Upper Bollinger Band 17.83
Lower Bollinger Band 10.95
Percent B (%b) 0.72
BandWidth 47.87
MACD Line 0.43
MACD Signal Line -0.04
MACD Histogram 0.4699
Fundamentals Value
Market Cap 711.92 Million
Num Shares 44.8 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -10.81
Price-to-Sales 11.55
Price-to-Book 0.00
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.15
Resistance 3 (R3) 22.78 21.34 21.10
Resistance 2 (R2) 21.34 19.74 21.02 20.75
Resistance 1 (R1) 18.61 18.76 17.89 17.98 20.41
Pivot Point 17.17 17.17 16.81 16.85 17.17
Support 1 (S1) 14.44 15.57 13.72 13.81 11.37
Support 2 (S2) 13.00 14.59 12.68 11.03
Support 3 (S3) 10.27 13.00 10.68
Support 4 (S4) 9.64